To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program Lead for their Early Pipeline Programs. To unlock the potential of next-generation human enzymes, Aeglea requires exceptional individuals who bring tremendous skill and talent with their experience. With 25+ years of experience in executive search, The Chase Group was able to utilize their vast network of life science professionals to identify the successful candidate. Reporting to the Chief Medical Officer, this respected and versatile leader is responsible for shaping the program strategy and generating data from clinical development activities. The Chase Group is honored to partner with Aeglea and support their dedication and passion to improve the lives of patients with unmet medical needs.
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program Lead for their Early Pipeline Programs. To unlock the potential of next-generation human enzymes, Aeglea requires exceptional individuals who bring tremendous skill and talent with their experience. With 25+ years of experience in executive search, The Chase Group was able to utilize their vast network of life science professionals to identify the successful candidate. Reporting to the Chief Medical Officer, this respected and versatile leader is responsible for shaping the program strategy and generating data from clinical development activities. The Chase Group is honored to partner with Aeglea and support their dedication and passion to improve the lives of patients with unmet medical needs.- Categories: Life Sciences
Arcturus Therapeutics Secures Head of Drug Safety Through Continued Partnership with The Chase Group
The Chase Group’s track record for success continues with another executive placement secured for Arcturus Therapeutics. Entering a new stage in clinical development, Arcturus retained…
Leadership Team Grows at Biologics Consulting Through Partnership with The Chase Group
Biologics Consulting, currently experiencing a season of growth, retained The Chase to build out their leadership team. Tasked with identifying a Regulatory Project Management Lead,…
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience….-
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development… 
Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…
The Chase Group Continues Successful Collaboration with Genmab Through Placement of Vice President, CDTL
The Chase Group, known for its thorough search capabilities and expertise in Life Sciences Executive Search, was retained by Genmab Pharmaceuticals to execute a critical…